阿托伐他汀在动脉硬化性脑梗死患者治疗中的临床价值分析

摘要

目的：研究阿托伐他汀在动脉硬化性脑梗死患者治疗中的临床价值。方法选择2012年1月～2013年10月江苏省连云港市第一人民医院接诊的100例动脉硬化性脑梗死患者进行研究。具体随机方法分为观察组和对照组。观察组50例患者，采用常规治疗加阿托伐他汀治疗。对照组50例患者，采用常规治疗。比较2组患者的临床治疗效果、治疗前后的炎症因子以及血脂。结果观察组患者与对照组患者一般临床资料相比无统计学差异；观察组患者与对照组患者治疗的总有效率为90.00％和70.00％，观察组患者的总有效率显著高于对照组，2组比较有统计学意义（u＝2.4696，P＝0.0135）；治疗前，2组患者的IL-6、hs-CRP、TG、TC、LDL-C和HDL-C均无统计学差异。治疗后，观察组患者的IL-6显著低于对照组，2者比较有统计学意义（P＜0.0001）；观察组患者的hs-CRP显著低于对照组，2者比较有统计学意义（P＜0.0001）；观察组患者的TG、TC、LDL-C均低于对照组，2者比较有统计学意义（P＜0.05）；观察组患者的HDL-C显著高于对照组，2者比较有统计学意义（P＜0.05）。结论阿托伐他汀在动脉硬化性脑梗死患者治疗中的临床效果良好，值得临床推广。%Objective To evaluate the clinical value analysis of atorvastatin in the treatment of patients with arteriosclerotic cerebral infarction. Methods 100 patients with atherosclerotic cerebral infarction from January 2012 to October 2013 in the first people's hospital of lianyungang were researched.They were divided randomly into observation and control groups.Observation group had 50 patients,they were treated by using of conventional treatment with atorvastatin therapy.Control group had 50 patients,using conventional therapy.Two groups'Clinical outcomes,inflammatory cytokines and lipids were compared.Results There was no significant difference in the control group and the observation group in the clinical data ;Total efficiency rate in the observation group and the control group was 90.00% and 70.00%,respectly.Total efficiency rate of observation group was higher than the control group,there was a significant difference (u=2.4696,P=0.0135 );before treatment,there was no significant difference of patients in the control group and the observation group in IL-6,hs-CRP,TG,TC,LDL-C and HDL-C;after treatment,IL-6 of observation group was lower than the control group,there was a significant difference (P<0.0001);hs-CRP of observation group was lower than the control group,there was a significant difference (P<0.0001);TG,TC,LDL-C of observation group was lower than the control group,there was a significant difference (P<0.05);HDL-C of observation group was higher than the control group,there was a significant difference (P<0.05).Conclusion The clinical value analysis of atorvastatin in the treatment of patients with arteriosclerotic cerebral infarction is well.It is worthy of promotion in clinic.